This article is more than 5 years old. Information may no longer be current.
Centrexion Therapeutics acquires three new analgesic candidates from Boehringer Ingelheim
Click Here to Manage Email Alerts
Centrexion Therapeutics recently announced the expansion of its proprietary pipeline with the acquisition of three new analgesic candidates from Boehringer Ingelheim.
The company’s proprietary pipeline reportedly consists of the first and only injectable analgesic capsaicin, known as trans-capsaicin, which is currently being evaluated in clinical trials for the treatment of pain associated with chronic conditions, according to a company press release. The financial details of the acquisition were not publically disclosed.
The first of the three analgesic therapies is CNTX-6970, a reportedly novel, potent and selective cytokine CCR2 antagonist with an analgesic profile. The second, CNTX-6016, is a “super selective” cannabinoid CB2 agonist. The third, CNTX-0290, is a first-in-class selective somatostatin SSTR4 agonist, which is a completely novel pain target, according to a press release from the company.
“The acquisition of three of Boehringer Ingelheim’s most promising pain treatment candidates strengthens our existing proprietary pipeline of therapies based on our patented and exclusive injectable trans-capsaicin. With a diversified and rapidly advancing pipeline and an experienced management team, Centrexion is poised to redefine the pain treatment market and transform the lives of people living with chronic pain,” Jeffrey Kinder, the chief executive officer of Centrexion Therapeutics, said in the release.
Reference: